# Sheila K Singh

## List of Publications by Year in Descending Order

**Source:** https://exaly.com/author-pdf/3390055/sheila-k-singh-publications-by-year.pdf
**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|---|---|---|---|
| 112 papers | 12,713 citations | 29 h-index | 112 g-index |
| 119 ext. papers | 14,179 ext. citations | 7.6 avg, IF | 5.99 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 112 | CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment. **2022**, 10, | | 4 |
| 111 | The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues.. *Frontiers in Oncology*, **2022**, 12, 815726 | 5.3 | |
| 110 | Childhood Medulloblastoma: An Overview.. *Methods in Molecular Biology*, **2022**, 2423, 1-12 | 1.4 | |
| 109 | Discovery of HDAC6-Selective Inhibitor NN-390 with Efficacy in Group 3 Medulloblastoma.. *Journal of Medicinal Chemistry*, **2022**, | 8.3 | 4 |
| 108 | Diversity among health care leaders in Canada: a cross-sectional study of perceived gender and race.. *Cmaj*, **2022**, 194, E371-E377 | 3.5 | 1 |
| 107 | Identification of five important genes to predict glioblastoma subtypes. *Neuro-Oncology Advances*, **2021**, 3, vdab144 | 0.9 | 1 |
| 106 | evaluation of CAR-T cells in patient-derived glioblastoma models. *STAR Protocols*, **2021**, 2, 100920 | 1.4 | 1 |
| 105 | Advances in Immunotherapy for Adult Glioblastoma. *Cancers*, **2021**, 13, | 6.6 | 2 |
| 104 | NGMA-5. An in vivo functional genomics screen to identify novel drivers of lung-to-brain metastasis. *Neuro-Oncology Advances*, **2021**, 3, ii5-ii5 | 0.9 | 78 |
| 103 | Intratumoral heterogeneity associated with glioblastoma drug response and resistance **2021**, 185-199 | | |
| 102 | ETS-Domain Transcription Factor Elk-1 Regulates Stemness Genes in Brain Tumors and CD133+ BrainTumor-Initiating Cells. *Journal of Personalized Medicine*, **2021**, 11, | 3.6 | 1 |
| 101 | BSCI-18. Identifying novel drivers of lung-to-brain metastasis through in vivo functional genomics. *Neuro-Oncology Advances*, **2021**, 3, iii5-iii5 | 0.9 | 78 |
| 100 | Delirium and other neuropsychiatric manifestations of COVID-19 infection in people with preexisting psychiatric disorders: a systematic review.. *Journal of Medical Case Reports*, **2021**, 15, 586 | 1.2 | 2 |
| 99 | Temporal profiling of therapy resistance in human medulloblastoma identifies novel targetable drivers of recurrence. *Science Advances*, **2021**, 7, eabi5568 | 14.3 | 0 |
| 98 | Assessing the Safety of a Cell-Based Immunotherapy for Brain Cancers Using a Humanized Model of Hematopoiesis. *STAR Protocols*, **2020**, 1, 100124 | 1.4 | |
| 97 | De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors. *Communications Biology*, **2020**, 3, 645 | 6.7 | 10 |
| 96 | RAD51-Mediated DNA Homologous Recombination Is Independent of Mutational Status. *Cancers*, **2020**, 12, | 6.6 | 6 |

| | | | |
|---|---|---|---|
| 95 | Development of a peptide-based delivery platform for targeting malignant brain tumors. *Biomaterials*, **2020**, 252, 120105 | 15.6 | 10 |
| 94 | The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. *Cell Stem Cell*, **2020**, 26, 832-844.e6 | 18 | 41 |
| 93 | Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma. *STAR Protocols*, **2020**, 1, 100174 | 1.4 | 2 |
| 92 | Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma. *Cell*, **2020**, 181, 1329-1345.e24 | 36.2 | 40 |
| 91 | A CD133-AKT-Wnt signaling axis drives glioblastoma brain tumor-initiating cells. *Oncogene*, **2020**, 39, 1590-1599 | 9.2 | 17 |
| 90 | Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors. *Frontiers in Immunology*, **2020**, 11, 599253 | 8.4 | 5 |
| 89 | A Patient-Derived Xenograft Model of Glioblastoma. *STAR Protocols*, **2020**, 1, 100179 | 1.4 | 2 |
| 88 | WNT: an unexpected tumor suppressor in medulloblastoma. *Molecular and Cellular Oncology*, **2020**, 7, 1834903 | 1.2 | 1 |
| 87 | Impact of COVID-19 and other pandemics and epidemics on people with pre-existing mental disorders: a systematic review protocol and suggestions for clinical care. *BMJ Open*, **2020**, 10, e040229 | 3 | 8 |
| 86 | Wnt activation as a therapeutic strategy in medulloblastoma. *Nature Communications*, **2020**, 11, 4323 | 17.4 | 13 |
| 85 | The Strange Case of Jekyll and Hyde: Parallels Between Neural Stem Cells and Glioblastoma-Initiating Cells. *Frontiers in Oncology*, **2020**, 10, 603738 | 5.3 | 1 |
| 84 | Deciphering brain tumor heterogeneity, one cell at a time. *Nature Medicine*, **2019**, 25, 1474-1476 | 50.5 | 5 |
| 83 | Predictive measures and outcomes of extent of resection in juvenile pilocytic astrocytoma. *Journal of Clinical Neuroscience*, **2019**, 70, 79-84 | 2.2 | 3 |
| 82 | A rapid in vitro methodology for simultaneous target discovery and antibody generation against functional cell subpopulations. *Scientific Reports*, **2019**, 9, 842 | 4.9 | 7 |
| 81 | Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells. *Journal of Neuro-Oncology*, **2019**, 143, 417-428 | 4.8 | 9 |
| 80 | Childhood cerebellar tumours mirror conserved fetal transcriptional programs. *Nature*, **2019**, 572, 67-73 | 50.4 | 149 |
| 79 | Regulation of the proline regulatory axis and autophagy modulates stemness in TP73/p73 deficient cancer stem-like cells. *Autophagy*, **2019**, 15, 934-936 | 10.2 | 9 |
| 78 | Salvage Therapy for Childhood Medulloblastoma: A Single Center Experience. *Canadian Journal of Neurological Sciences*, **2019**, 46, 403-414 | 1 | 3 |

| | | | |
|---|---|---|---|
| 77 | A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. *Cancer Cell*, **2019**, 36, 51-67.e7 | 24.3 | 39 |
| 76 | MEDU-44. MUSASHI-1 IS A MASTER REGULATOR OF ABERRANT TRANSLATION IN GROUP 3 MEDULLOBLASTOMA. *Neuro-Oncology*, **2019**, 21, ii112-ii113 | 1 | 78 |
| 75 | Flow Cytometric Analysis of Brain Tumor Stem Cells. *Methods in Molecular Biology*, **2019**, 1869, 69-77 | 1.4 | 1 |
| 74 | Introduction to Brain Tumor Stem Cells. *Methods in Molecular Biology*, **2019**, 1869, 1-9 | 1.4 | 6 |
| 73 | TAp73 Modifies Metabolism and Positively Regulates Growth of Cancer Stem-Like Cells in a Redox-Sensitive Manner. *Clinical Cancer Research*, **2019**, 25, 2001-2017 | 12.9 | 13 |
| 72 | In Vivo Murine Models of Brain Metastasis. *Methods in Molecular Biology*, **2019**, 1869, 231-238 | 1.4 | 1 |
| 71 | BMI1 is a therapeutic target in recurrent medulloblastoma. *Oncogene*, **2019**, 38, 1702-1716 | 9.2 | 11 |
| 70 | EPH Profiling of BTIC Populations in Glioblastoma Multiforme Using CyTOF. *Methods in Molecular Biology*, **2019**, 1869, 155-168 | 1.4 | 3 |
| 69 | In Vitro Assays for Screening Small Molecules. *Methods in Molecular Biology*, **2019**, 1869, 189-196 | 1.4 | |
| 68 | In Vitro Self-Renewal Assays for Brain Tumor Stem Cells. *Methods in Molecular Biology*, **2019**, 1869, 79-84 | 1.4 | 4 |
| 67 | Differentiation of Brain Tumor Initiating Cells. *Methods in Molecular Biology*, **2019**, 1869, 85-91 | 1.4 | 1 |
| 66 | Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. *Nature*, **2018**, 553, 101-105 | 50.4 | 116 |
| 65 | Introduction to Cancer Stem Cells: Past, Present, and Future. *Methods in Molecular Biology*, **2018**, 1692, 1-16 | 1.4 | 12 |
| 64 | EMT: Mechanisms and therapeutic implications. *Pharmacology & Therapeutics*, **2018**, 182, 80-94 | 13.9 | 205 |
| 63 | Therapeutic Targeting of the Premetastatic Stage in Human Lung-to-Brain Metastasis. *Cancer Research*, **2018**, 78, 5124-5134 | 10.1 | 24 |
| 62 | Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis. *Lancet, The*, **2018**, 391, 1197-1204 | 40 | 70 |
| 61 | Biopsy Versus Subtotal Versus Gross Total Resection in Patients with Low-Grade Glioma: A Systematic Review and Meta-Analysis. *World Neurosurgery*, **2018**, 120, e762-e775 | 2.1 | 15 |
| 60 | Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells. *Cell Death and Disease*, **2018**, 9, 990 | 9.8 | 13 |

| | | | |
|---|---|---|---|
| 59 | Association of Glioblastoma Multiforme Stem Cell Characteristics, Differentiation, and Microglia Marker Genes with Patient Survival. *Stem Cells International*, **2018**, 2018, 9628289 | 5 | 22 |
| 58 | Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma. *Cancer Research*, **2018**, 78, 5023-5037 | 10.1 | 30 |
| 57 | Evaluating overweight and obesity prevalence in survivors of childhood brain tumors: a systematic review protocol. *Systematic Reviews*, **2017**, 6, 43 | 3 | 4 |
| 56 | Development of an Atypical Teratoid Rhabdoid Tumor in a Meningioma. *International Journal of Surgical Pathology*, **2017**, 25, 567-572 | 1.2 | 4 |
| 55 | Atraumatic versus traumatic lumbar puncture needles: a systematic review and meta-analysis protocol. *BMJ Open*, **2017**, 7, e014478 | 3 | 4 |
| 54 | Adiposity in childhood brain tumors: A report from the Canadian Study of Determinants of Endometabolic Health in Children (CanDECIDE Study). *Scientific Reports*, **2017**, 7, 45078 | 4.9 | 8 |
| 53 | Brain tumor initiating cells: with great technology will come greater understanding. *Future Neurology*, **2017**, 12, 223-236 | 1.5 | 0 |
| 52 | RNAi screen identifies essential regulators of human brain metastasis-initiating cells. *Acta Neuropathologica*, **2017**, 134, 923-940 | 14.3 | 19 |
| 51 | Convergence of BMI1 and CHD7 on ERK Signaling in Medulloblastoma. *Cell Reports*, **2017**, 21, 2772-2784 | 10.6 | 19 |
| 50 | Progression of atypical extraventricular neurocytoma to anaplastic ganglioglioma. *Human Pathology*, **2017**, 59, 125-130 | 3.7 | 10 |
| 49 | The use of ibuprofen and acetaminophen for acute headache in the postconcussive youth: A pilot study. *Paediatrics and Child Health*, **2017**, 22, 2-6 | 0.7 | 11 |
| 48 | Preclinical Modeling and Therapeutic Avenues for Cancer Metastasis to the Central Nervous System. *Frontiers in Oncology*, **2017**, 7, 220 | 5.3 | 2 |
| 47 | The effectiveness of interventions to treat obesity in survivors of childhood brain tumors: a systematic review protocol. *Systematic Reviews*, **2016**, 5, 101 | 3 | 4 |
| 46 | Development of a Patient-Derived Xenograft Model Using Brain Tumor Stem Cell Systems to Study Cancer. *Methods in Molecular Biology*, **2016**, 1458, 231-45 | 1.4 | 3 |
| 45 | The identification of human pituitary adenoma-initiating cells. *Acta Neuropathologica Communications*, **2016**, 4, 125 | 7.3 | 19 |
| 44 | Subdural Hematoma Mimickers: A Systematic Review. *World Neurosurgery*, **2016**, 93, 73-80 | 2.1 | 15 |
| 43 | A novel stem cell culture model of recurrent glioblastoma. *Journal of Neuro-Oncology*, **2016**, 126, 57-67 | 4.8 | 12 |
| 42 | A Balanced Protocol for Return to School for Children and Youth Following Concussive Injury. *Clinical Pediatrics*, **2015**, 54, 783-92 | 1.2 | 53 |

| | | | |
|---|---|---|---|
| 41 | Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells. *Clinical Cancer Research*, **2015**, 21, 5324-37 | 12.9 | 29 |
| 40 | Flow-Cytometric Identification and Characterization of Neural Brain Tumor-Initiating Cells for Pathophysiological Study and Biomedical Applications **2015**, 199-211 | | |
| 39 | Development of a conservative protocol to return children and youth to activity following concussive injury. *Clinical Pediatrics*, **2015**, 54, 152-63 | 1.2 | 24 |
| 38 | Endovascular Thrombectomy for Acute Ischemic Stroke: A Meta-analysis. *JAMA - Journal of the American Medical Association*, **2015**, 314, 1832-43 | 27.4 | 307 |
| 37 | Isolation and Identification of Neural Cancer Stem/Progenitor Cells **2015**, 145-167 | | |
| 36 | Reply to Letter: "What Ingredients Have You Used to Prepare This Delicious Lunch? A Critical Look Behind a Meta-analysis". *Annals of Surgery*, **2015**, 262, e114-5 | 7.8 | |
| 35 | MicroRNA Regulation of Brain Tumour Initiating Cells in Central Nervous System Tumours. *Stem Cells International*, **2015**, 2015, 141793 | 5 | 18 |
| 34 | The role of stem cells in pediatric central nervous system malignancies. *Advances in Experimental Medicine and Biology*, **2015**, 853, 49-68 | 3.6 | 6 |
| 33 | Temporal evolution of medulloblastoma subgroups. *Journal of Neurosurgery: Pediatrics*, **2015**, 16, 349-50 | 2.1 | |
| 32 | Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. *Neuro-Oncology*, **2015**, 17, 868-81 | 1 | 91 |
| 31 | STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation. *Oncotarget*, **2015**, 6, 27461-77 | 3.3 | 37 |
| 30 | Culture and Isolation of Brain Tumor Initiating Cells. *Current Protocols in Stem Cell Biology*, **2015**, 34, 3.3.1-3.3.13 | 2.8 | 3 |
| 29 | Glioblastoma Stem Cells Drive Tumor Recurrence and Patient Relapse **2014**, 193-208 | | 1 |
| 28 | Brain metastasis-initiating cells: survival of the fittest. *International Journal of Molecular Sciences*, **2014**, 15, 9117-33 | 6.3 | 18 |
| 27 | Brain Tumor Genomics **2014**, 321-338 | | |
| 26 | Chronic subdural hematoma management: a systematic review and meta-analysis of 34,829 patients. *Annals of Surgery*, **2014**, 259, 449-57 | 7.8 | 221 |
| 25 | Revealed: The spy who regulates neuroblastoma stem cells. *Oncotarget*, **2014**, 5, 11014-6 | 3.3 | 1 |
| 24 | Generation of murine xenograft models of brain tumors from primary human tissue for in vivo analysis of the brain tumor-initiating cell. *Methods in Molecular Biology*, **2014**, 1210, 37-49 | 1.4 | 2 |

| | | | |
|---|---|---|---|
| 23 | Medulloblastoma stem cells: modeling tumor heterogeneity. *Cancer Letters*, **2013**, 338, 23-31 | 9.9 | 25 |
| 22 | FoxG1 interacts with Bmi1 to regulate self-renewal and tumorigenicity of medulloblastoma stem cells. *Stem Cells*, **2013**, 31, 1266-77 | 5.8 | 43 |
| 21 | Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children. *Cancer Research*, **2013**, 73, 6734-44 | 10.1 | 70 |
| 20 | A cancer stem cell model for studying brain metastases from primary lung cancer. *Journal of the National Cancer Institute*, **2013**, 105, 551-62 | 9.7 | 43 |
| 19 | Evolution of brain tumor-initiating cell research: in pursuit of a moving target. *Future Neurology*, **2013**, 8, 1-3 | 1.5 | 1 |
| 18 | Investigating the link between molecular subtypes of glioblastoma, epithelial-mesenchymal transition, and CD133 cell surface protein. *PLoS ONE*, **2013**, 8, e64169 | 3.7 | 63 |
| 17 | Bmi1 marks intermediate precursors during differentiation of human brain tumor initiating cells. *Stem Cell Research*, **2012**, 8, 141-53 | 1.6 | 42 |
| 16 | GBM secretome induces transient transformation of human neural precursor cells. *Journal of Neuro-Oncology*, **2012**, 109, 457-66 | 4.8 | 14 |
| 15 | Processing of primary brain tumor tissue for stem cell assays and flow sorting. *Journal of Visualized Experiments*, **2012**, | 1.6 | 12 |
| 14 | Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice. *Stem Cells*, **2012**, 30, 1064-75 | 5.8 | 53 |
| 13 | Medulloblastoma stem cells: where development and cancer cross pathways. *Pediatric Research*, **2012**, 71, 516-22 | 3.2 | 47 |
| 12 | Origins of Metastasis-Initiating Cells **2012**, 229-246 | | |
| 11 | YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. *Cancer Research*, **2011**, 71, 5569-78 | 10.1 | 64 |
| 10 | Cancer Stem Cells in Brain Cancer **2011**, 37-56 | | 1 |
| 9 | From birth till death: neurogenesis, cell cycle, and neurodegeneration. *Anatomical Record*, **2009**, 292, 1953-61 | 2.1 | 19 |
| 8 | Culture and isolation of brain tumor initiating cells. *Current Protocols in Stem Cell Biology*, **2009**, Chapter 3, Unit3.3 | 2.8 | 16 |
| 7 | Brain tumor stem cells: identification and concepts. *Neurosurgery Clinics of North America*, **2007**, 18, 31-8, viii | 4 | 47 |
| 6 | Cancer stem cells in nervous system tumors. *Oncogene*, **2004**, 23, 7267-73 | 9.2 | 584 |

| | | | |
|---|---|---|---|
| 5 | Identification of human brain tumour initiating cells. *Nature*, **2004**, 432, 396-401 | 50.4 | 5869 |
| 4 | Identification of a cancer stem cell in human brain tumors. *Cancer Research*, **2003**, 63, 5821-8 | 10.1 | 3368 |
| 3 | Cerebral salt wasting: truths, fallacies, theories, and challenges. *Critical Care Medicine*, **2002**, 30, 2575-9 | 1.4 | 172 |
| 2 | A method to estimate urinary electrolyte excretion in patients at risk for developing cerebral salt wasting. *Journal of Neurosurgery*, **2001**, 95, 420-4 | 3.2 | 28 |
| 1 | Childhood Cerebellar Tumors Mirror Conserved Fetal Transcriptional Programs | | 5 |